Weight loss jab Mounjaro linked to lower dementia risk
The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity.
Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. https://t.co/WhHodrztS1 pic.twitter.com/Rll5Eg3ycU — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025
Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic.
GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed.
The other half used other anti-diabetic medication.
📢Important update
Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025.
✅Around 1,000 people in Dorset will qualify under strict national criteria
✅No need to contact your doctor
More: https://t.co/ml4QJgZ224 pic.twitter.com/uURpuIuYzx — NHS Dorset (@NHSDorset) June 23, 2025
During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke.
They were also 30% less likely to die during the follow-up period.
And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40.
They found no differences in Parkinson's disease or brain bleeds.
The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings.
Recommended reading:
'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open.
Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity.
'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain.
'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions.
'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
Recommended reading:
Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia.
'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity.
'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear.
'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
an hour ago
- The Guardian
Demand for weight loss drugs is becoming unsustainable, say pharmacists
Demand for weight loss drugs is becoming so 'unsustainable' that demand may soon outstrip supply, pharmacists have warned. The National Pharmacy Association (NPA) said supply problems could encourage people to turn to unregulated online sources, despite the risks involved. The number of people in the UK using drugs such as Wegovy and Mounjaro has soared to well above a million, with most patients paying to get them privately. During April, 1.6m packs of Mounjaro and Wegovy were bought in Britain, with the number thought to correlate closely with the number of people using them. 'Spiralling demand for weight loss medication risks going far beyond what is clinically deliverable', the NPA said. The drugs might need to be reserved for those in greatest need because they are so overweight instead of being given to the 'worried well', it added. New polling has found that 21% of Britons have tried to get hold of the medications over the past year, a figure that rises to 35% among 18- to 34-year-olds. The same survey found that 41% of all age groups would use them if they were free on the NHS. This figure rose to 64% among those aged 25-34. Savanta interviewed a representative sample of 2,002 adults aged 18 or over online from 20-23 June for the NPA, which represents 6,000 independent pharmacies. 'Weight loss jabs are one of the biggest drug innovations this century but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it,' said Olivier Picard, the NPA's chair. 'It's clear from this polling that more people are interested in getting weight loss jabs than can benefit from weight loss medication.' Supply of the medicines has been hit by shortages in some parts of the UK, including for higher doses of Mounjaro, the NPA said. Supply has been restricted to some pharmacies, which has stopped some new patients from going on to the drugs. The Medicines and Healthcare products Regulatory Agency, the UK's drugs watchdog, has warned patients to obtain the drugs only with a doctor's prescription, and not from beauty parlours or websites. A Department of Health spokesperson said more people would be able to obtain 'revolutionary' weight loss jabs over the next few years. 'Weight loss drugs are a powerful tool in tackling the obesity crisis head-on as part of our 10-year health plan', they added. 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to do so in a safe and controlled way. We will ensure that those most in need will receive treatment first.' About 220,000 people in England are due to be offered tirzepatide, a diabetes drug that promotes weight loss, over the next three years. Pharmacies already provide about 85% of all weight loss drugs and need to be closely involved in the expansion of access, Picard added. 'The government should use the massive untapped expertise and skills of pharmacists to help speed up the NHS's weight loss medication programme to millions of the most in need patients,' he said.
South Wales Guardian
3 hours ago
- South Wales Guardian
Pharmacies warn of unsustainable demand for weight loss medication
Many more patients are interested in using weight loss medication than are actually suitable for treatment, according to the National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies. Some 21% of people who were interviewed in a NPA-commissioned poll agreed they had attempted to access weight loss treatments in the last year, either online or in person at a pharmacy, rising to 35% of 16 to 34-year-olds. This is compared to only 7% of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Leader Live
3 hours ago
- Leader Live
Pharmacies warn of unsustainable demand for weight loss medication
Many more patients are interested in using weight loss medication than are actually suitable for treatment, according to the National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies. Some 21% of people who were interviewed in a NPA-commissioned poll agreed they had attempted to access weight loss treatments in the last year, either online or in person at a pharmacy, rising to 35% of 16 to 34-year-olds. This is compared to only 7% of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
